Literature DB >> 29206818

HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.

Chalermrat Bunchorntavakul1, Rajender K Reddy2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29206818     DOI： 10.1038/ajg.2017.435

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  15 in total

Review 1.  Optimum timing of treatment for hepatitis C infection relative to liver transplantation.

Authors:  Audrey Coilly; Bruno Roche; Jean-Charles Duclos-Vallée; Didier Samuel
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09-08

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

3.  Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Authors:  Varun Saxena; Vandana Khungar; Elizabeth C Verna; Josh Levitsky; Robert S Brown; Mohamed A Hassan; Mark S Sulkowski; Jacqueline G O'Leary; Farrukh Koraishy; Joseph S Galati; Alexander A Kuo; Monika Vainorius; Lucy Akushevich; David R Nelson; Michael W Fried; Norah Terrault; K Rajender Reddy
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

4.  Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis.

Authors:  Patrick G Northup; Curtis K Argo; Dennis T Nguyen; Maureen A McBride; Sean C Kumer; Timothy M Schmitt; Timothy L Pruett
Journal:  Transpl Int       Date:  2010-10       Impact factor: 3.782

Review 5.  Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.

Authors:  C Bunchorntavakul; K Rajender Reddy
Journal:  J Viral Hepat       Date:  2016-03-28       Impact factor: 3.728

6.  Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.

Authors:  Nabiha Faisal; Marc Bilodeau; Bandar Aljudaibi; Geri Hirsch; Eric M Yoshida; Trana Hussaini; Maged P Ghali; Stephen E Congly; Mang M Ma; Jennifer Leonard; Curtis Cooper; Kevork Peltekian; Eberhard L Renner; Leslie B Lilly
Journal:  Transplantation       Date:  2016-05       Impact factor: 4.939

7.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Authors:  Luca Saverio Belli; Marina Berenguer; Paolo Angelo Cortesi; Mario Strazzabosco; Susanne-Rasoul Rockenschaub; Silvia Martini; Cristina Morelli; Francesca Donato; Riccardo Volpes; Georges-Philippe Pageaux; Audrey Coilly; Stefano Fagiuoli; Giuliana Amaddeo; Giovanni Perricone; Carmen Vinaixa; Gabriela Berlakovich; Rita Facchetti; Wojciech Polak; Paolo Muiesan; Christophe Duvoux
Journal:  J Hepatol       Date:  2016-05-17       Impact factor: 25.083

8.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.

Authors:  Fred Poordad; Eugene R Schiff; John M Vierling; Charles Landis; Robert J Fontana; Rong Yang; Fiona McPhee; Eric A Hughes; Stephanie Noviello; Eugene S Swenson
Journal:  Hepatology       Date:  2016-03-07       Impact factor: 17.425

9.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Authors:  Graham R Foster; William L Irving; Michelle C M Cheung; Alex J Walker; Benjamin E Hudson; Suman Verma; John McLauchlan; David J Mutimer; Ashley Brown; William T H Gelson; Douglas C MacDonald; Kosh Agarwal
Journal:  J Hepatol       Date:  2016-01-30       Impact factor: 30.083
View more
  2 in total

Review 1.  Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges.

Authors:  Sirina Ekpanyapong; K Rajender Reddy
Journal:  United European Gastroenterol J       Date:  2019-03-21       Impact factor: 4.623

2.  A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus.

Authors:  Prasanta Debnath; Sanjay Chandnani; Pravin Rathi; Sujit Nair; Parmeshwar Junare; Suhas Udgirkar; Anupam Singh; Qais Contractor
Journal:  Clin Exp Hepatol       Date:  2020-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.